Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

NeuroVive Announces Publication of Phase I Clinical Trial of CicloMulsion® in Clinical Drug Investigation


News provided by

NeuroVive Pharmaceutical AB

03 Dec, 2012, 09:35 GMT

Share this article

Share toX

Share this article

Share toX

LUND, Sweden, December 3, 2012 /PRNewswire/ --

NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion® in the scientific journal Clinical Drug Investigation. The paper highlights that the intravenous cyclosporine formulation CicloMulsion® demonstrates bioequivalence and improved tolerability when compared with Sandimmune® Injection.

The mitochondrial medicine company NeuroVive Pharmaceutical today announces publication of the Phase I clinical study comparing CicloMulsion®, the Cremophor®-free intravenous cyclosporine formula (also known under the product name NeuroSTAT®), to Sandimmune® Injection. The results of the trial that were first announced by NeuroVive in 2010 have now been published in the peer-reviewed journal Clinical Drug Investigation.

The paper, titled "Bioequivalence and Tolerability Assessment of a Novel Intravenous Ciclosporine Lipid Emulsion Compared to Branded Ciclosporine in Cremophor® EL", highlights that primary and secondary endpoints of the trial were met demonstrating that CicloMulsion® is bioequivalent to Sandimmune® Injection and is safe and well tolerated. The full paper can be downloaded on the publisher website by accessing the following link:

http://link.springer.com/article/10.1007/s40261-012-0029-x

CicloMulsion®, a Cremophor®-free formulation of the cyclophilin inhibitor cyclosporine, is in clinical development by NeuroVive for the treatment of cardiac reperfusion injury. Under the name NeuroSTAT® the formulation is also being developed for the treatment of traumatic brain injury. The active ingredient cyclosporine acts by preventing the death of mitochondria in damaged cells and the following cascade of intracellular biochemical events that lead to secondary tissue damage. By protecting a cell's mitochondria, NeuroVive's products ensure that energy production is preserved and a damaged cell's normal regenerative mechanisms can act to repair and maintain the cell.

The paper reports the Phase I bioequivalence, safety and tolerability study in which 52 healthy volunteers were administered single intravenous doses of each of the two cyclosporine formulations in a randomized single-blind cross-over washout design. All pharmacokinetic variables (including the FDA and EMA required parameters) were within the range required to show bioequivalence.

The proportion of adverse events was significantly higher when subjects were treated with Sandimmune® compared to CicloMulsion®. Two serious adverse events requiring qualified medical treatment were recorded in subjects receiving Sandimmune®. As a result, the study protocol was changed and all subjects received protective pre-medication. CicloMulsion® was safe and well tolerated.

Eskil Elmer, CSO of NeuroVive Pharmaceutical and senior author of the publication, said:

"The publication of the results of the Phase I trial with our novel intravenous formulation for cyclosporine in this quality peer-reviewed journal is an important step of the go-to-market strategy for our products for treatment of traumatic brain injury and cardiac reperfusion injury. The trial clearly shows that our formulation is bioequivalent to Sandimmune®, yet free from Sandimmune®'s risk of causing anaphylactic and hypersensitivity reactions, thus providing a firm foundation on which to bring CicloMulsion® and NeuroSTAT® to cardiac and brain injured patients. NeuroSTAT® is expected to soon enter a Phase II clinical trial in patients with severe traumatic brain injury and CicloMulsion® is currently in a 1000-patient Phase III trial for cardiac reperfusion injury."

In addition to the full publication, further information on the Phase I clinical study can be found at ClinicalTrials.gov by accessing the following link: http://clinicaltrials.gov/ct2/show/NCT01692834

The novel Cremophor®-free formulation for cyclosporine

CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications. They have the following advantages:

(i) Ready-to-use solution. The ready-to-hang-and-administer bottles do not require dilution from a concentrate, thus reducing measuring and dosing errors.

(ii) Formulated with physiological fats and phospholipids that can be readily metabolized by the human body.

(iii) No risk of Cremophor® EL-related severe hypersensitivity reactions or anaphylactic reactions.

(iv) No risk of Cremophor® EL-related cyto-, nephro- and cardiotoxicity.

Cremophor® EL

Cremophor® EL is a detergent-like agent used to keep lipophilic drugs in solution. Cremophor® EL is implicated in hypersensitivity and anaphylactic reactions. For most Cremophor®-containing intravenous drugs, like Taxol®, corticosteroids are a required premedication to reduce the risk of these reactions. Cremophor® is not usually present in newer drug formulations for this safety reason, including the propofol intravenous anesthetic Diprivan® and the paclitaxel intravenous chemotherapeutic agent Abraxane®. Sandimmune® Injection contains Cremophor®. CicloMulsion® is Cremophor®-free.

About NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB (http://www.neurovive.com) is a leading mitochondrial medicine company, developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.

NeuroVive's products for neuro- and cardioprotection are based on the cyclophilin inhibitor cyclosporine that prevents the death of mitochondria in distressed cells and the subsequent cascade of intracellular biochemical events, thereby protecting cellular energy supply and reducing secondary tissue damage.

NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries following stenting of coronary arteries after myocardial infarction. CicloMulsion® is currently in a 1,000-patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction. The study is entitled "Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients (CIRCUS)". Information on the Phase III clinical study can be found at ClinicalTrials.gov by accessing the following link: http://clinicaltrials.gov/ct2/show/NCT01502774

NeuroVive is also developing the cyclophilin inhibitor NeuroSTAT® which is soon expected to enter a Phase II clinical trial in patients with severe traumatic brain injury. Both cardiac reperfusion injury and traumatic brain injury are indications with huge unmet medical need and no approved pharmaceutical treatment options.

NeuroVive's pipeline includes a cyclophilin D inhibitor for stroke and drug candidates aimed at mitochondrial energy deficiency.

NeuroVive´s shares are listed on the Swedish trading platform AktieTorget (http://www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

Key Contact: Mikael Bronnegard, CEO
Email: info@neurovive.com
Phone No: +46(0)70-299-62-64

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.